Opaganib

• Description :

  Opaganib (ABC294640) is a selective, competitive sphingosine kinase 2 (SK2) inhibitor with Ki of 9.8 μM.

• Product Name Alternative :

  ABC294640

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  SphK

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ABC294640.html

• Purity :

  99.94

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1(C2)CC3(C4=CC=C(Cl)C=C4)CC2CC(C3)C1)NCC5=CC=NC=C5

• Molecular Formula :

  C23H25ClN2O

• Molecular Weight :

  380.91

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]French KJ, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010 Apr;333 (1) :129-39.|[2]Beljanski V, et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec;29 (6) :1132-42.|[3]Shi Y, et al. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan;56 (1) :137-45.|[4]Liu Q, et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012;7 (7) :e41834.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [915385-81-8]